Identification of common differentially expressed genes in urinary bladder cancer

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Zaravinos, Apostolos ^a   Lambrou, George I ^b   Boulalas, Ioannis ^a,c   Delakas, Dimitris ^c   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHASE PROMOTING COMPLEX; B CELL MATURATION ANTIGEN; BINDING PROTEIN; BONE MORPHOGENETIC PROTEIN 4; CARRIER PROTEIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTOFERRIN; LIM PROTEIN; RECEPTOR INTERACTING PROTEIN 140; RNA; TRANSCRIPTION FACTOR YY1; UNCLASSIFIED DRUG; TRANSCRIPTION FACTOR; TUMOR MARKER; MESSENGER RNA;

ACTC1 GENE; AGED; ARTICLE; BLADDER CANCER; BMP4 GENE; CANCER GRADING; CDC20 GENE; CELL COMMUNICATION; CHROMOSOME 1; CHROMOSOME 11; CHROMOSOME 2; CHROMOSOME 21; CONTROLLED STUDY; CRYGD GENE; CYSTECTOMY; DBH GENE; DOWN REGULATION; GENE CLUSTER; GENE EXPRESSION; GENETIC ANALYSIS; GJB1 GENE; HCCS GENE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KRT83 GENE; LHCGR GENE; MFAP4 GENE; MICROARRAY ANALYSIS; MPZ GENE; NHLH1 GENE; NUCLEOTIDE SEQUENCE; PREVALENCE; PRINCIPAL COMPONENT ANALYSIS; RNA METABOLISM; SIGNAL TRANSDUCTION; SPARCL1 GENE; TACR3 GENE; TAGLN GENE; TM9SF1 GENE; TMP2 GENE; TUMOR GENE; UPREGULATION; ADULT; APOPTOSIS; BLADDER CARCINOGENESIS; CANCER INVASION; CELL DEATH; CELL PROLIFERATION; CELL SHAPE; CLINICAL ARTICLE; CYTOSKELETON; DNA REPAIR; FEMALE; MALE; METABOLISM; METASTASIS; TUMOR VASCULARIZATION; BLADDER TUMOR; CASE CONTROL STUDY; CHROMOSOME MAP; CLUSTER ANALYSIS; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; IMMUNOHISTOCHEMISTRY; METHODOLOGY; GENETIC DATABASE; GENOMICS; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE;

AGED; CASE-CONTROL STUDIES; CHROMOSOME MAPPING; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; ADULT; DATABASES, GENETIC; FEMALE; GENOMICS; MIDDLE AGED; RNA, MESSENGER; SURVIVAL RATE;

EID: 79953682249     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018135     Document Type: Article

References (88)

1. Lopez-Beltran A, Montironi R, (2004) Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 46: 170-176.
2. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537.
3. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, et al. (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7: 673-679.
4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
5. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
6. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, et al. (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24: 227-235.
7. Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, et al. (2001) Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A 98: 9754-9759.
8. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
9. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON, (2010) Identification of a cell of origin for human prostate cancer. Science 329: 568-571.
10. Greene FL, Sobin LH, (2008) The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin 58: 180-190.
11. Wu W, Dave N, Tseng GC, Richards T, Xing EP, et al. (2005) Comparison of normalization methods for CodeLink Bioarray data. BMC Bioinformatics 6: 309.
12. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, et al. (2006) The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24: 1151-1161.
13. Diez D, Alvarez R, Dopazo A, (2007) Codelink: an R package for analysis of GE healthcare gene expression bioarrays. Bioinformatics 23: 1168-1169.
14. Altman NS, Hua J, (2006) Extending the loop design for two-channel microarray experiments. Genet Res 88: 153-163.
15. Churchill GA, (2002) Fundamentals of experimental design for cDNA microarrays. Nat Genet 32 (Suppl): 490-495.
16. Townsend JP, (2003) Multifactorial experimental design and the transitivity of ratios with spotted DNA microarrays. BMC Genomics 4: 41.
17. Dyrskjot L, (2003) Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarrays in cancer diagnostics. Expert Rev Mol Diagn 3: 635-647.
18. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, et al. (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64: 4040-4048.
19. Mengual L, Burset M, Ars E, Lozano JJ, Villavicencio H, et al. (2009) DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. J Urol 182: 741-748.
20. Monzon FA, Lyons-Weiler M, Buturovic LJ, Rigl CT, Henner WD, et al. (2009) Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 27: 2503-2508.
21. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, et al. (2007) Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 7: 64.
22. Sirbu A, Ruskin HJ, Crane M, (2010) Cross-platform microarray data normalisation for regulatory network inference. PLoS One 5: e13822.
23. Ramasamy A, Mondry A, Holmes CC, Altman DG, (2008) Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Med 5: e184.
24. Kollegal M, Adak S, Shippy R, Sendera T, (2005) Considerations in Making Microarray Cross-Platform Correlations. Computational Systems Bioinformatics Conference, Workshops and Poster Abstracts. IEEE pp. 101-102.
25. Yauk CL, Berndt ML, Williams A, Douglas GR, (2004) Comprehensive comparison of six microarray technologies. Nucleic Acids Res 32: e124.
26. Klipper-Aurbach Y, Wasserman M, Braunspiegel-Weintrob N, Borstein D, Peleg S, et al. (1995) Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses 45: 486-490.
27. Storey JD, Tibshirani R, (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100: 9440-9445.
28. Storey JD, Tibshirani R, (2003) Statistical methods for identifying differentially expressed genes in DNA microarrays. Methods Mol Biol 224: 149-157.
29. Quackenbush J, (2001) Computational analysis of microarray data. Nat Rev Genet 2: 418-427.
30. Cohen BA, Mitra RD, Hughes JD, Church GM, (2000) A computational analysis of whole-genome expression data reveals chromosomal domains of gene expression. Nat Genet 26: 183-186.
31. Sturn A, Quackenbush J, Trajanoski Z, (2002) Genesis: cluster analysis of microarray data. Bioinformatics 18: 207-208.
32. Reyal F, Stransky N, Bernard-Pierrot I, Vincent-Salomon A, de Rycke Y, et al. (2005) Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes-a study of 130 invasive ductal breast carcinomas. Cancer Res 65: 1376-1383.
33. Cole SW, Yan W, Galic Z, Arevalo J, Zack JA, (2005) Expression-based monitoring of transcription factor activity: the TELiS database. Bioinformatics 21: 803-810.
34. Wingender E, Dietze P, Karas H, Knuppel R, (1996) TRANSFAC: a database on transcription factors and their DNA binding sites. Nucleic Acids Res 24: 238-241.
35. Zhang B, Schmoyer D, Kirov S, Snoddy J, (2004) GOTree Machine (GOTM): a web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies. BMC Bioinformatics 5: 16.
36. Beisvag V, Junge FK, Bergum H, Jolsum L, Lydersen S, et al. (2006) GeneTools-application for functional annotation and statistical hypothesis testing. BMC Bioinformatics 7: 470.
37. Zhang B, Kirov S, Snoddy J, (2005) WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33: W741-748.
38. Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, et al. (2003) Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 163: 505-516.
39. Sanchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, et al. (2002) Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 62: 6973-6980.
40. Duggan BJ, McKnight JJ, Williamson KE, Loughrey M, O'Rourke D, et al. (2003) The need to embrace molecular profiling of tumor cells in prostate and bladder cancer. Clin Cancer Res 9: 1240-1247.
41. Thykjaer T, Workman C, Kruhoffer M, Demtroder K, Wolf H, et al. (2001) Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res 61: 2492-2499.
42. Ying-Hao S, Qing Y, Lin-Hui W, Li G, Rong T, et al. (2002) Monitoring gene expression profile changes in bladder transitional cell carcinoma using cDNA microarray. Urol Oncol 7: 207-212.
43. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, et al. (2003) Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33: 90-96.
44. Mor O, Nativ O, Stein A, Novak L, Lehavi D, et al. (2003) Molecular analysis of transitional cell carcinoma using cDNA microarray. Oncogene 22: 7702-7710.
45. Modlich O, Prisack HB, Pitschke G, Ramp U, Ackermann R, et al. (2004) Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res 10: 3410-3421.
46. Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, et al. (2010) A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 17: 348-361.
47. Kim IY, Lee DH, Lee DK, Kim WJ, Kim MM, et al. (2004) Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1. Cancer Res 64: 7355-7360.
48. Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Nakamura Y, et al. (2008) CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27: 1562-1571.
49. Shi Y, Lee JS, Galvin KM, (1997) Everything you have ever wanted to know about Yin Yang 1. Biochim Biophys Acta 1332: F49-66.
50. Sui G, Affar el B, Shi Y, Brignone C, Wall NR, et al. (2004) Yin Yang 1 is a negative regulator of p53. Cell 117: 859-872.
51. Gronroos E, Terentiev AA, Punga T, Ericsson J, (2004) YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc Natl Acad Sci U S A 101: 12165-12170.
52. Kim JD, Yu S, Kim J, (2009) YY1 is autoregulated through its own DNA-binding sites. BMC Mol Biol 10: 85.
53. Seligson D, Horvath S, Huerta-Yepez S, Hanna S, Garban H, et al. (2005) Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol 27: 131-141.
54. Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, et al. (2009) The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle 8: 1367-1372.
55. Zaravinos A, Spandidos DA, (2009) Yin Yang 1 as a prognostic factor. Cell Cycle 8: 1305.
56. Zaravinos A, Spandidos DA, (2010) Yin yang 1 expression in human tumors. Cell Cycle 9: 512-522.
57. Zhong H, May MJ, Jimi E, Ghosh S, (2002) The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 9: 625-636.
58. Reese DH, Politano VA, (1979) A rationale for the loss of growth control during experimental bladder carcinogenesis. Med Hypotheses 5: 1007-1015.
59. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, et al. (2009) Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 106: 14016-14021.
60. Czerniak B, Chaturvedi V, Li L, Hodges S, Johnston D, et al. (1999) Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 18: 1185-1196.
61. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C, (2010) Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 28: 401-408.
62. Matsumoto M, Kawakami K, Enokida H, Toki K, Matsuda R, et al. (2010) CpG hypermethylation of human four-and-a-half LIM domains 1 contributes to migration and invasion activity of human bladder cancer. Int J Mol Med 26: 241-247.
63. Li Z, Burzawa JK, Troung A, Feng S, Agoulnik IU, et al. (2009) Relaxin signaling in uterine fibroids. Ann N Y Acad Sci 1160: 374-378.
64. Klonisch T, Bialek J, Radestock Y, Hoang-Vu C, Hombach-Klonisch S, (2007) Relaxin-like ligand-receptor systems are autocrine/paracrine effectors in tumor cells and modulate cancer progression and tissue invasiveness. Adv Exp Med Biol 612: 104-118.
65. Bohgaki M, Tsukiyama T, Nakajima A, Maruyama S, Watanabe M, et al. (2008) Involvement of Ymer in suppression of NF-kappaB activation by regulated interaction with lysine-63-linked polyubiquitin chain. Biochim Biophys Acta 1783: 826-837.
66. Enesa K, Ito K, Luong le A, Thorbjornsen I, Phua C, et al. (2008) Hydrogen peroxide prolongs nuclear localization of NF-kappaB in activated cells by suppressing negative regulatory mechanisms. J Biol Chem 283: 18582-18590.
67. Enesa K, Zakkar M, Chaudhury H, Luong le A, Rawlinson L, et al. (2008) NF-kappaB suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling. J Biol Chem 283: 7036-7045.
68. Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, et al. (2007) Differential gene expression patterns and interaction networks in BCR-ABL-positive and-negative adult acute lymphoblastic leukemias. J Clin Oncol 25: 1341-1349.
69. Liu J, Guo Q, Chen B, Yu Y, Lu H, et al. (2006) Cathepsin B and its interacting proteins, bikunin and TSRC1, correlate with TNF-induced apoptosis of ovarian cancer cells OV-90. FEBS Lett 580: 245-250.
70. Kraemer K, Schmidt U, Fuessel S, Herr A, Wirth MP, et al. (2006) Microarray analyses in bladder cancer cells: inhibition of hTERT expression down-regulates EGFR. Int J Cancer 119: 1276-1284.
71. Zhou Y, Atkins JB, Rompani SB, Bancescu DL, Petersen PH, et al. (2007) The mammalian Golgi regulates numb signaling in asymmetric cell division by releasing ACBD3 during mitosis. Cell 129: 163-178.
72. Nishioka H, Haraoka J, (2005) Significance of immunohistochemical expression of Rab3B and SNAP-25 in growth hormone-producing pituitary adenomas. Acta Neuropathol 109: 598-602.
73. Rotondo F, Scheithauer BW, Kovacs K, Bell DC, (2009) Rab3B immunoexpression in human pituitary adenomas. Appl Immunohistochem Mol Morphol 17: 185-188.
74. Abedin SA, Thorne JL, Battaglia S, Maguire O, Hornung LB, et al. (2009) Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. Carcinogenesis 30: 449-456.
75. Chang TS, Jeong W, Lee DY, Cho CS, Rhee SG, (2004) The RING-H2-finger protein APC11 as a target of hydrogen peroxide. Free Radic Biol Med 37: 521-530.
76. Wasch R, Robbins JA, Cross FR, (2010) The emerging role of APC/CCdh1 in controlling differentiation, genomic stability and tumor suppression. Oncogene 29: 1-10.
77. Yang X, Wood PA, Ansell CM, Quiton DF, Oh EY, et al. (2009) The circadian clock gene Per1 suppresses cancer cell proliferation and tumor growth at specific times of day. Chronobiol Int 26: 1323-1339.
78. Zhu Y, Stevens RG, Hoffman AE, Fitzgerald LM, Kwon EM, et al. (2009) Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res 69: 9315-9322.
79. Kakar S, Muir T, Murphy LM, Lloyd RV, Burgart LJ, (2003) Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma. Am J Clin Pathol 119: 361-366.
80. Li Y, Yu DC, Chen Y, Amin P, Zhang H, et al. (2001) A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 61: 6428-6436.
81. Ramakrishna M, Williams LH, Boyle SE, Bearfoot JL, Sridhar A, et al. (2010) Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PLoS One 5: e9983.
82. Langat DL, Wheaton DA, Platt JS, Sifers T, Hunt JS, (2008) Signaling pathways for B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in human placenta. Am J Pathol 172: 1303-1311.
83. Chen B, Wang X, Zhao W, Wu J, (2010) Klotho inhibits growth and promotes apoptosis in human lung cancer cell line A549. J Exp Clin Cancer Res 29: 99.
84. Halleck M, Davis HR, Kirschmeier P, Levitan D, Snyder RD, et al. (2009) An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach. Toxicology 258: 116-130.
85. Jiang C, Ito M, Piening V, Bruck K, Roeder RG, et al. (2004) TIP30 interacts with an estrogen receptor alpha-interacting coactivator CIA and regulates c-myc transcription. J Biol Chem 279: 27781-27789.
86. Brolinson A, Fourcade S, Jakobsson A, Pujol A, Jacobsson A, (2008) Steroid hormones control circadian Elovl3 expression in mouse liver. Endocrinology 149: 3158-3166.
87. Mansure JJ, Nassim R, Kassouf W, (2009) Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol Ther 8: 6-15.
88. Marks F, Furstenberger G, Muller-Decker K, (2007) Tumor promotion as a target of cancer prevention. Recent Results Cancer Res 174: 37-47.